"Rob Abbott on the value of HEOR for biotech startups"

On this week's episode of the Business of Biotech, ISPOR—The Professional Society for Health Economics and Outcomes Research CEO Rob Abbott talks about how HEOR can help early and mid-stage biotechs attract investment dollars by helping to differentiate drug development candidates. Cost-of-illness studies, burden-of-disease analyses, and payer landscape assessments are a few of the tools that can build a case for a drug's market value; Rob explains how companies can set up an HEOR function, as well as how AI, real world evidence, and patient-centered research are being used to improve trial design and accelerates market access. To watch the full episode, click the link in the comments 👇

For startup and early-stage #biotech companies, health economics and outcomes research (HEOR) is often misunderstood as something to address late in the development process. Recently, I joined the Life Science Leader’s Business of Biotech podcast with Ben Comer to discuss why and how HEOR can be a strategic lever from day one. From burden-of-disease studies to payer landscape assessments, HEOR offers critical insights and real-world validations that shape smarter decisions earlier in the pipeline. And with AI and patient-centered research reshaping the field, the opportunity to integrate HEOR into innovation strategy has never been greater. I invite you to listen and share your perspective: How can we ensure HEOR is embedded earlier in the startup journey to serve as a strategic driver of better evidence, stronger investment and broader patient access? https://lnkd.in/gKuZ_j8k #AIinHealthcare

In our latest demo, we put Mindbreeze InSpire to the test with the topic of postbiotics. Traditionally, a researcher could spend hours or even days digging through PubMed and internal data to answer critical questions. With Mindbreeze, it happens instantly. 𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐀𝐈 + 𝐑𝐞𝐭𝐫𝐢𝐞𝐯𝐚𝐥-𝐀𝐮𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 → Synthesized, evidence-based answers directly from PubMed content. 𝐅𝐚𝐜𝐞𝐭𝐞𝐝 𝐟𝐢𝐥𝐭𝐞𝐫𝐢𝐧𝐠 → Date, category, keywords, MEDDRA ontology, contributors, funding, and more. 𝟑𝟔𝟎° 𝐯𝐢𝐞𝐰 𝐨𝐟 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 → Key clinical trials, connected concepts, top authors, funding sources, and institutions. 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐛𝐮𝐢𝐥𝐭-𝐢𝐧 → Every answer backed by a bibliography for traceability. In under 5 minutes, we move from a broad topic to: • A refined set of high-quality research • Mapped connections between concepts • A clear view of the experts and funders shaping the field Mindbreeze doesn’t just find documents — it connects the dots and empowers faster, more informed decisions. Watch the video to see it in action. What research questions would you like to explore with Mindbreeze?

Scientific transparency matters as much as discovery itself. On October 9 2025, Nature Communications issued an Author Correction to its June 2025 article, “Metabolic modeling reveals a multi-level deregulation of host-microbiome metabolic networks in IBD.” The update adds Stefan Schreiber, previously omitted, to the author list and revises the “Competing interests” section to include appropriate disclosures. These editorial corrections ensure full credit and transparency but do not alter the article’s data or conclusions about how metabolic pathways are disrupted in inflammatory bowel disease. The correction underscores the journal’s commitment to accuracy in authorship and conflict disclosure—core principles that sustain trust in biomedical research. Source: https://lnkd.in/eX5_kXwN Published Date: October 07, 2025 👉 Comment BIOHACK if you want more science and health news like this! #BiohackYourself #HealthNews #ScienceNews #ResearchUpdates #Biohack Disclaimer: This content is for educational and entertainment purposes only and is not a substitute for medical advice. Always consult a healthcare professional. Full disclaimer: https://lnkd.in/eJE9Rsty 🧠 We explore all angles — ancient wisdom, modern science, and everything in between. No allegiance to Big Pharma or Big Natural. 🔍 We cite studies, but encourage you to read them, question funding, and review the methods. Stay curious. 📚 Not all journals are equal. Peer-reviewed ≠ perfect. Check the source, think critically, and decide for yourself. ⚠️ One study isn’t the full story. Science evolves. We’re here to inform, not to tell you what to believe.

🎬 New Video Alert: The Final Word Matters Click the 🔗👇 for free access to first 100 and more: https://lnkd.in/dH5EMhY7 Click the 🔗👇for full threeminutes Thesis video: https://lnkd.in/dynzyY9z 📢 Excited to unveil the Discussion & Conclusion section of my recently published double peer-reviewed and quadruple author proved research — now indexed in PubMed and featured in a reputable journal Perspectives in Clinical Research (PICR) healthscience journal Wolters Kluwer Health 🧠📚 This video distills the clinical implications, limitations, and future directions of our work in epilepsy treatment optimization — where evidence meets ethics, and data meets decision-making. 🔍 What’s inside: How our findings challenge conventional assumptions namely Breakthrough seizures (BTS) and adverse drugs reaction occuring despite therapeutic drug levels in pts' blood Real-world relevance for clinicians, researchers, and policymakers A transparent reflection on strengths, gaps, and next steps 🎯 Why it matters: The discussion isn’t just a wrap-up — it’s where science speaks to practice. This section bridges the gap between statistical significance and clinical meaning, and I’m proud to share it with the community. 📽️ Watch the video, share your thoughts, and let’s advance the conversation on methodological integrity, evidence translation, and open science. #ResearchPublication #PubMed #EpilepsyResearch #EvidenceBasedMedicine #TherapeuticDrugsMonitoring #DiscussionMatters #AcademicPublishing #ScienceCommunication #LinkedInResearch #OpenScience #ClinicalImpact

📢 Just published: Quantifying #DrugTarget #ResidenceTime with mathematical rigour 😊 ➕ ➖ ➗ 🟰 😊 : We are excited to share this new QSPainRelief-funded paper by Ortiz et al. (2025) from Jesús Giraldo's team at the Universitat Autònoma de Barcelona: 📰 https://lnkd.in/dQ3QfGPy Background: 💊 Drug-target residence time (RT) is a crucial parameter in #BindingKinetics, influencing #efficacy, #specificity, and off-target effects. But until now, the field has lacked a unified theoretical approach to quantify it properly. What the authors did: 💡 Developed a mathematical formalism to define and compute RT robustly 💡 Showed how it can be integrated with experimental binding data 💡 Demonstrated applications in #DrugDesign workflows Why this is exciting: ⭐ This work provides a foundation for more rational and quantitative comparisons of candidate molecules, beyond classical metrics like affinity. ⭐ It helps bring theory closer to experimental practice in #pharmacology. Ideas - How could this be applied in your projects? #DrugDiscovery #Pharmacokinetics #ComputationalPharmacology Elizabeth (Liesbeth) De Lange Nadia Malliou Dr. Petra Bloms-Funke Jan Freijer Dr. Sara Stöber European Health and Digital Executive Agency (HaDEA) European Pain Federation EFIC Pain Alliance Europe IMI-PainCare

Earlier this year, top #RareDisease experts—researchers, clinicians, industry professionals, and regulatory leaders—came together in Washington, D.C., for the inaugural #NORD Rare Disease Scientific Symposium. We celebrated breakthroughs and engaged in meaningful conversations about solving the remaining challenges in rare disease science. Weren't able to attend? Learn how to access all session recordings and check out some of our top takeaways, including: ✅ Innovative clinical trial designs ✅ Regulatory insights from the FDA on #biomarkers and trial flexibility ✅ How real-world data and #AI are reshaping rare disease research ...and so much more! Keep reading here: https://bit.ly/4mYoFCp -- #ScientificSymposium #ClinicalTrials #AIinHealthcare #RealWorldEvidence

How do you choose the right path when every option matters? In his latest article, Paul tackles one of the hardest challenges for early-stage biotechs: indication prioritisation. Every potential path has patients in need, a scientific rationale, and a commercial promise. The real question is how to weigh those opportunities and make trade-offs with conviction. Paul shares a recent client example where fragmented data was turned into a structured decision framework that gave the team confidence to move forward. 👉 Read Paul’s full piece here:

Innovation rarely comes from the “average” case — it comes from studying the outliers. Yet modern medicine gives doctors little time to explore them. I’ve seen this firsthand: -A rheumatoid arthritis patient with sky-high antibodies and joint damage — but no pain. -Another with normal labs and perfect X-rays — but reports excruciating pain - Some people eat “everything under the sun” and stay lean. Others eat little and struggle to lose weight. These are the cases that don’t fit the textbook. But they’re also the ones that push medicine forward. The problem? Medical training rewards pattern recognition — not curiosity. We learn to match, not to wonder. If we gave clinicians more space to explore anomalies instead of dismissing them, we might unlock the next generation of insights in autoimmune disease, metabolism, and beyond. Maybe the real frontier in medicine isn’t more data — …it’s deeper curiosity. Curious to hear your thoughts Paulius Mui, MD.

𝗖𝗵𝗼𝗼𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝗖𝗥𝗢 𝗰𝗮𝗻 𝗺𝗮𝗸𝗲 𝗼𝗿 𝗯𝗿𝗲𝗮𝗸 𝘆𝗼𝘂𝗿 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝘀𝘁𝘂𝗱𝘆. In a market where everyone claims expertise, the real difference comes down to access, agility, and accountability. At PBL Assay Science, our scientific experts are involved from day one, helping you move faster, design smarter, and deliver data that stands up to scrutiny. Read the full blog to see how researchers are rethinking CRO partnerships in 2025. https://lnkd.in/ecZKjSfq